drugset
drugset / Trial / NCT04392830

A Study to Investigate the Safety, Tolerability, Pharmacokinetics of ALZ002 DS in Healthy Volunteers

NCT04392830 ↗

Phase 1 Completed 72 enrolled AnnJi Pharmaceutical Co., Ltd.
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single-ascending and multiple-ascending doses of ALZ002 DS.

Timeline

Start
2020-05-11
Primary completion
2021-04-28
Completion
2021-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject ALZ002 DS Unknown — Oral

Indications

No indication recorded.